Current Status of Research and Treatments for Prostate Cancer
Author Information
Author(s): J. Waxman, A. Saini
Primary Institution: Royal Postgraduate Medical School, Hammersmith Hospital
Hypothesis
Is total androgen blockade beneficial in treating prostate cancer?
Conclusion
The study suggests that while total androgen blockade may offer some advantages, the overall impact on survival is minimal.
Supporting Evidence
- Combination therapy showed a median time to progression of 16 months compared to 14 months for monotherapy.
- Median survival was 35 months for combination therapy versus 28 months for monotherapy.
- Only one of nine trials showed prolonged survival with total androgen blockade.
Takeaway
Doctors are trying to find the best way to treat prostate cancer, and some treatments might help a little, but they don't make a big difference in how long people live.
Methodology
The study involved a clinical trial comparing combination therapy with leuprolide and flutamide to leuprolide alone.
Potential Biases
There may be biases due to the retrospective nature of some studies and the involvement of local physicians in treatment decisions.
Limitations
The study's findings are based on a limited number of trials and may not represent all patients.
Participant Demographics
The study included over 600 patients with advanced prostate cancer.
Want to read the original?
Access the complete publication on the publisher's website